title: Crystal structure of (S)-2-[(3S,8S,9S,10R,13S,14S,17R)-3-hy-droxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetra-deca-hydro-1H-cyclo-penta[a]phenanthren-17-yl]-N-meth-oxy-N-methyl-pro-pan-amide (Fernholz Weinreb amide).
abstract: The literature compound 3β-hy-droxy-bis-nor-5-cholenic aldehyde is an important inter-mediate for the synthesis of new modulators of the nuclear oxysterol receptor Liver X. As part of our ongoing search for new LXR antagonists, the title compound, C24H39NO3, has proven to be an important inter-mediate in our new synthetic pathway, giving the corresponding aldehyde in high yield and in only three steps from the commercially available 3β-hy-droxy-bis-nor-5-cholenic acid. The title amide crystallized with two mol-ecules in the asymmetric unit, linked into helices by O-H⋯O hydrogen bonds involving the hy-droxy and carbonyl groups.
authors.affiliation: School of Pharmacy, University of Oslo, PO Box 1068 Blindern, N-0316 Oslo, Norway.
authors.forename: Elvar Ørn
authors.initials: EØ
authors.lastname: Viktorsson
authors.affiliation: School of Pharmacy, University of Oslo, PO Box 1068 Blindern, N-0316 Oslo, Norway.
authors.forename: Ove Alexander Høgmoen
authors.initials: OA
authors.lastname: Åstrand
authors.affiliation: School of Pharmacy, University of Oslo, PO Box 1068 Blindern, N-0316 Oslo, Norway.
authors.forename: Rasha Sabah
authors.initials: RS
authors.lastname: Haseeb
authors.affiliation: Department of Chemistry, University of Oslo, PO Box 1033 Blindern, N-0315 Oslo, Norway.
authors.forename: Carl Henrik
authors.initials: CH
authors.lastname: Görbitz
authors.affiliation: School of Pharmacy, University of Oslo, PO Box 1068 Blindern, N-0316 Oslo, Norway.
authors.forename: Pål
authors.initials: P
authors.lastname: Rongved
keywords: Liver X receptor; crystal structure; obesity; steroid
references.citation: Shock. 2011 Apr;35(4):367-74
references.pmid: 20926989
references.citation: ACS Med Chem Lett. 2012 Aug 28;3(10):828-33
references.pmid: 24900386
references.citation: Bioorg Med Chem. 2014 Jan 1;22(1):643-50
references.pmid: 24268541
references.citation: Acta Crystallogr B. 2002 Apr;58(Pt 2):260-4
references.pmid: 11910163
references.citation: Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5419-24
references.pmid: 12697904
references.citation: J Nat Prod. 2001 Oct;64(10):1266-72
references.pmid: 11678648
references.citation: Res Lett Biochem. 2008;2008:801849
references.pmid: 22820672
references.citation: Angew Chem Int Ed Engl. 2014 Jan 13;53(3):662-71
references.pmid: 24382699
references.citation: Bioorg Med Chem. 2009 Apr 1;17(7):2864-70
references.pmid: 19272781
references.citation: Mol Med Rep. 2012 Apr;5(4):895-900
references.pmid: 22267249
references.citation: Mol Cell Endocrinol. 2012 Apr 4;351(2):129-41
references.pmid: 21907760
references.citation: Chem Commun (Camb). 2013 Oct 7;49(77):8586-98
references.pmid: 23959006
references.citation: Trends Pharmacol Sci. 2012 Jul;33(7):394-404
references.pmid: 22541735
references.citation: Expert Opin Ther Targets. 2011 Feb;15(2):219-32
references.pmid: 21204733
references.citation: Acta Crystallogr A. 2008 Jan;64(Pt 1):112-22
references.pmid: 18156677
references.citation: Eur J Med Chem. 2014 Mar 3;74:258-63
references.pmid: 24480357